'Highest risk-highest benefit' strategy: a pragmatic, cost-effective approach to targeting use of PCSK9 inhibitor therapies.
Lieven Annemans;
Chris J Packard;
Andrew Briggs 
;
Kausik K Ray;
(2018)
'Highest risk-highest benefit' strategy: a pragmatic, cost-effective approach to targeting use of PCSK9 inhibitor therapies.
EUROPEAN HEART JOURNAL, 39 (27).
pp. 2546-2550.
ISSN 0195-668X
DOI: 10.1093/eurheartj/ehx710
;
Kausik K Ray;
(2018)
'Highest risk-highest benefit' strategy: a pragmatic, cost-effective approach to targeting use of PCSK9 inhibitor therapies.
EUROPEAN HEART JOURNAL, 39 (27).
pp. 2546-2550.
ISSN 0195-668X
DOI: 10.1093/eurheartj/ehx710
-
picture_as_pdf - Highest risk-highest benefit strategy a pragmatic, cost-effective approach to targeting use of PCSK9 inhibitor therapies.pdf
-
subject - Published Version
-
- Available under Creative Commons: 3.0
Downloads